INTERNATIONAL PRACTICE OF ABATACEPT USE IN TREATMENT OF REFRACTORY UVEITIS IN PATIENTS WITH IDIOPATHIC JUVENILE ARTHRITIS
Abstract
Key words: children, juvenile idiopathic arthritis, uveitis, treatment, abatacept, lymphocyte co-stimulation blockade, biological treatment.
(Voprosy sovremennoi pediatrii — Current Pediatrics. — 2011; 10 (5): 39–44.)
About the Authors
R.V. DenisovaE.I. Alexeeva
References
1. Saurenmann R.K., Levin A.V., Feldman B.M. et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long term follow up study. Arthritis. Rheum. 2007; 56: 647–657.
2. Heiligenhaus A., Mingels A., Heinz C., Ganser G. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti–inflammatory medication. Eur. J. Ophthalmol. 2007; 17: 743–748.
3. Tappeiner C., Roesel M., Heinz C. et al. Limited value of cyclosporine for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye. 2009; 23: 1192–1198.
4. Doycheva D., Deuter C., Stuebiger N. et al. Mycophenolate mofetil in the treatment of uveitis in children. Br. J. Ophthalmol. 2007; 91: 180–184.
5. Sharma S.M., Ramanan A.V., Riley P., Dick A.D. Use of infliximab in juvenile onset rheumatological disease associated refractory uveitis: efficacy in joint and ocular disease [letter]. Ann. Rheum. Dis. 2007; 66: 840–841.
6. Biester S., Deuter C., Michels H. et al. Adalimumab in the therapy of uveitis in childhood. Br. J. Ophthalmol. 2007; 91: 319–324.
7. Pettit A.R., Thomas R. Dendritic cells: the driving force behind autoimmunity in rheumatoid arthritis. Immunol. Cell. Biol. 1999; 7: 420–427.
8. Bretscher P.A. A two step, two signal model for the primary activation of precursor helper T– cells. Proc. Natl. Acad. Sci. USA. 1999; 96: 85–90.
9. Choy E.H., Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. New Engl. J. Med. 2001; 344: 907–916.
10. Yamada A., Salama A.D., Sayegh M.H. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J. Am. Soc. Nephrol. 2002; 13: 559–575.
11. Chambers C.A., Allison J.P. CTLA–4 — the costimulatory molecule that doesn't: regulation of T-cell responses by inhibition. Cold. Spring. Harb. Symp. Quant. Biol. 1999; 64: 303–312.
12. Davies P., Zhou L., Abraham R. Abatacept binds to the Fc receptor CD64 but does not mediate complement dependent сytotoxicity or antibody dependent cellular cytotoxicity. J. Rheumatol. 2007; 34: 280–289.
13. Linsley P.S., Brady W., Urnes M. et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 1991; 174 (3): 561–569.
14. Ruperto N., Lovell D.J., Quartier P. et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo controlled withdrawal trial. Lancet. 2008; 372 (9636): 383–391.
15. Алексеева Е.И., Денисова Р.В., Валиева С.И. Абатацепт — новые возможности терапии ювенильного идиопатического артрита. Вопросы современной педиатрии. 2009; 8 (4): 84–89.
16. Angeles-Han S., Flynn T., Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis — a case report. J. Rheumatol. 2008; 35 (9): 1897–1898.
17. Zulian F., Balzarin M., Falcini F. Abatacept for Severe anti-tumor necrosis factor α refractory juvenile idiopathic arthritis — related uveitis. Arthritis. Care. Research. 2010; 62 (6): 821–825.
18. Kenawy N., Cleary G., Mewar D. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis associated uveitis. Graefes. Arch. Clin. Exp. Ophthalmol. 2011; 249 (2): 297–300.
19. Elhai M., Deslandre C.J., Kahan A. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases.Arthritis. Care. Res. (Hoboken). 2011; 63 (2): 307–308.
20. Silver P.B., Hathcock K.S., Chan C.C. et al. Blockade of costimulation through B7/CD28 inhibits experimental autoimmune uveoretinitis, but does not induce long term tolerance. J. Immunol. 2000; 165: 5041–5047.
21. Shao H., Woon M.D., Nakamura S. et al. Requirement of B7–mediated costimulation in the induction of experimental autoimmune anterior uveitis. Invest. Ophthalmol. Vis. Sci. 2001; 42: 2016–2021.
22. Deschenes J., Char D.H., Kaleta S. Activated T lymphocytes in uveitis. Br. J. Ophthalmol. 1988; 72: 83–87.
23. Wang X.C., Norose K., Yano A. et al. Two color flow cytometric analysis of activated T lymphocytes in aqueous humor of patients with endogenous vs. exogenous uveitis. Curr. Eye. Res. 1995; 14: 425–433.
Review
For citations:
Denisova R., Alexeeva E. INTERNATIONAL PRACTICE OF ABATACEPT USE IN TREATMENT OF REFRACTORY UVEITIS IN PATIENTS WITH IDIOPATHIC JUVENILE ARTHRITIS. Current Pediatrics. 2011;10(5):39-44.
Email this article 
